Biodexa Pharmaceuticals annual stock-based compensation
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Biodexa Pharmaceuticals Stock-Based Compensation Growth & History (BDRX)
Biodexa Pharmaceuticals's stock-based compensation was £170,000 for fiscal 2025.
View full Biodexa Pharmaceuticals company overviewBiodexa Pharmaceuticals annual stock-based compensation history
| Fiscal year | Period ended | Stock-based compensation | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | £170,000 | −£113,000 | −39.93% |
| 2024 | 2024-12-31 | £283,000 | £255,000 | +910.71% |
| 2023 | 2023-12-31 | £28,000 | −£95,000 | −77.24% |
| 2022 | 2022-12-31 | £123,000 | £34,000 | +38.20% |
| 2021 | 2021-12-31 | £89,000 | −£315,000 | −77.97% |
| 2020 | 2020-12-31 | £404,000 | £370,000 | +1088.24% |
| 2019 | 2019-12-31 | £34,000 | −£2,000 | −5.56% |
| 2018 | 2018-12-31 | £36,000 | −£484,000 | −93.08% |
| 2017 | 2017-12-31 | £520,000 | £317,000 | +156.16% |
| 2016 | 2016-12-31 | £203,000 | £33,000 | +19.41% |
| 2015 | 2015-12-31 | £170,000 | — | — |
Biodexa Pharmaceuticals stock-based compensation trends
Over the last five fiscal years, Biodexa Pharmaceuticals's stock-based compensation decreased from £404,000 to £170,000, a change of −£234,000.
About the metric
What stock-based compensation means
Stock-based compensation is the expense associated with equity awards such as restricted stock and employee options. It is a non-cash expense when recognized, but it can dilute existing shareholders unless offset by share repurchases.
Calculation and source
SEC-reported stock-based compensation
TickerStat standardizes share-based compensation reported in company SEC filings. The history shows recognized compensation expense or its cash-flow-statement adjustment, not the grant-date value of new awards or a forecast of future dilution. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Biodexa Pharmaceuticals source filings ↗Community posts
Biodexa advances trial enrollment as research spending and cash use rise
Biodexa ($BDRX) reported that 92 of the planned 168 participants have entered its Serenta trial, while first-half research and development spending increased to £2.92 million from £1.67 million. Spending reflected the trial and manufacturin ...